Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.Katz, B.A., Sprengeler, P.A., Luong, C., Verner, E., Elrod, K., Kirtley, M., Janc, J., Spencer, J.R., Breitenbucher, J.G., Hui, H., McGee, D., Allen, D., Martelli, A., Mackman, R.L.
(2001) Chem Biol 8: 1107-1121
- PubMed: 11731301
- DOI: https://doi.org/10.1016/s1074-5521(01)00084-9
- Primary Citation of Related Structures:
1GJ4, 1GJ5, 1GJ6, 1GJ7, 1GJ8, 1GJ9, 1GJA, 1GJB, 1GJC, 1GJD
- PubMed Abstract:
Involved or implicated in a wide spectrum of diseases, trypsin-like serine proteases comprise well studied drug targets and anti-targets that can be subdivided into two major classes. In one class there is a serine at position 190 at the S1 site, as in urokinase type plasminogen activator (urokinase or uPA) and factor VIIa, and in the other there is an alanine at 190, as in tissue type plasminogen activator (tPA) and factor Xa. A hydrogen bond unique to Ser190 protease-arylamidine complexes between O gamma(Ser190) and the inhibitor amidine confers an intrinsic preference for such inhibitors toward Ser190 proteases over Ala190 counterparts.
Axys Pharmaceutical Corporation, 385 Oyster Point Boulevard, South San Francisco, CA 94080, USA. firstname.lastname@example.org